11 Facts About Genitourinary Syndrome of Menopause That Go Beyond Dryness
The dryness conversation felt almost embarrassing to have, which meant it took far too long to bring up — and even longer to realise that the recurrent UTIs, the stinging when running, and the changed sensation during sex were all part of the same thing. Nobody had connected those dots, and that's exactly why this page exists.
Learn more about Rose →GSM Is the Official Medical Term That Replaced 'Vaginal Atrophy'
In 2014, the International Society for the Study of Women's Sexual Health and the Menopause Society formally retired the term 'vaginal atrophy' because it failed to capture how many structures are affected. GSM now encompasses changes to the vagina, vulva, labia, clitoris, urethra, and bladder — all of which are estrogen-sensitive tissues. The name change also acknowledged that 'atrophy' felt stigmatising, which discouraged women from raising the subject with their doctors.
Estrogen Receptors Line the Entire Lower Urinary Tract
The urethra, bladder trigone (the triangular base of the bladder), and pelvic floor muscles all carry estrogen receptors, which is why falling estrogen levels affect far more than vaginal tissue. When those receptors are no longer adequately stimulated, the tissues thin, lose collagen, and become less elastic — a process called urogenital atrophy. This explains why bladder and urinary symptoms are classified under GSM rather than treated as separate, unrelated problems.
The Labia Minora Can Shrink and Partially Fuse Over Time
Without adequate estrogen, the labia minora gradually lose fatty tissue and elasticity, sometimes thinning to the point where they are barely visible — a change clinicians call labial resorption. In more advanced cases, the labia can begin to adhere to surrounding tissue, narrowing the vaginal opening in a process similar to what occurs in lichen sclerosus. This is one of the structural changes that makes GSM a progressive condition rather than a static one, and it underscores why early treatment matters.
Vaginal pH Rises Significantly, Changing the Bacterial Environment
The healthy premenopausal vagina maintains an acidic pH of roughly 3.8–4.5, largely sustained by Lactobacillus bacteria whose survival depends on estrogen-driven glycogen production. As estrogen declines, glycogen decreases, Lactobacilli populations drop, and vaginal pH can rise above 5 — sometimes reaching 6 or 7. This shift makes the environment more hospitable to pathogenic bacteria, increasing susceptibility to bacterial vaginosis and changing vaginal odour and discharge in ways that many women notice before they notice dryness.
Recurrent Urinary Tract Infections Are a Core GSM Symptom
Recurrent UTIs — typically defined as two or more in six months — are significantly more common after menopause, and GSM is one of the primary drivers. Thinning urethral tissue, elevated vaginal pH, and reduced protective mucus all lower the barrier to bacterial colonisation. Studies have found that local vaginal estrogen therapy reduces recurrent UTIs in postmenopausal women, which confirms the biological link between estrogen loss and infection risk rather than treating them as coincidental.
Urgency and Overactive Bladder Are Directly Linked to GSM
The sudden, difficult-to-defer urge to urinate — often called urgency or overactive bladder (OAB) — has a well-documented relationship with estrogen deficiency. Estrogen helps maintain the sensory threshold of the bladder, and when levels fall, the bladder can become hypersensitive, firing urgency signals at lower volumes of urine. Nocturia (waking at night to urinate) also increases, and many women are prescribed OAB medications without anyone first addressing the underlying hormonal driver.
Stress Urinary Incontinence Has a Separate Mechanism But Overlaps with GSM
Stress urinary incontinence (leaking urine with a cough, sneeze, laugh, or jump) is driven primarily by weakened pelvic floor muscles and reduced urethral closure pressure — both of which estrogen decline contributes to. While pelvic floor dysfunction has multiple causes, the loss of collagen and connective tissue elasticity in the urethra and pelvic fascia that occurs with GSM directly worsens urethral support. The overlap means treating GSM can sometimes improve stress incontinence, though pelvic floor physiotherapy remains a cornerstone treatment in its own right.
Reduced Clitoral Sensitivity Is a Recognised Part of GSM
The clitoris contains estrogen receptors, and as estrogen declines, blood flow to clitoral tissue can decrease and the clitoral hood may partially retract or adhere — reducing tactile sensitivity and the capacity for arousal. Women often describe needing more stimulation to feel anything, or noticing that orgasms are less intense or harder to reach. This is a physiological change, not a psychological one, and it is part of the GSM picture even though it rarely appears on symptom checklists in a GP's office.
Painful Sex (Dyspareunia) Affects Roughly Half of Postmenopausal Women
Estimates from large population studies suggest that anywhere from 40 to 60 percent of postmenopausal women experience dyspareunia — pain during or after penetrative sex — with GSM as the leading physiological cause. Thinning vaginal walls, reduced lubrication, loss of rugae (the ridged folds that allow the vagina to expand), and elevated pH that inflames sensitive tissue all contribute. Critically, dyspareunia is not an inevitable or untreatable consequence of menopause; effective treatments exist, and avoiding sex entirely without treatment tends to worsen tissue atrophy over time.
Unlike Vasomotor Symptoms, GSM Does Not Improve Without Treatment
Hot flushes and night sweats tend to peak in early perimenopause and gradually diminish for many women over time — but GSM follows the opposite trajectory. Because the underlying cause is sustained estrogen deficiency rather than the hormonal volatility of transition, genitourinary tissues continue to change as long as estrogen remains low. Studies confirm that GSM symptoms worsen progressively with time since menopause, making early recognition and treatment more protective than a 'wait and see' approach.
Local Vaginal Estrogen Is Considered Safe for Most Women, Including Many Breast Cancer Survivors
Low-dose local vaginal estrogen (creams, pessaries, or rings applied directly to the vaginal tissue) delivers estrogen at doses so small that systemic absorption is minimal, which is why major menopause societies consider it appropriate for the majority of women — including many who are advised against systemic HRT. For breast cancer survivors, the guidance is more nuanced and depends on cancer type and treatment, but leading oncology bodies have shifted toward supporting its use in many cases after weighing quality-of-life evidence. Women are encouraged to have a specific conversation with their oncologist rather than assuming it is off-limits.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.